View More Recent Stories
-
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
-
Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
-
Exact Sciences (EXAS) Gains with Conf. Presentation Ongoing
-
Exact Sciences (EXAS) Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
-
Exact Sciences (EXAS) PT Lowered to $67 at Benchmark
-
Exact Sciences (EXAS) Tops Q2 EPS by 25c, provides guidance
-
Exact Sciences (EXAS) and TwinStrand Biosciences Enter Exclusive License Agreement for Duplex Sequencing Technology
-
Exact Sciences (EXAS) Slips 5% After Rival Colorectal Cancer Test Approved by FDA
-
Bernstein Cautious on Exact Sciences (EXAS)
-
Piper Sandler Reiterates Overweight Rating on Exact Sciences (EXAS)
-
Scotiabank Starts Exact Sciences (EXAS) at Sector Outperform
-
Exact Sciences (EXAS) seeking 25% price hike on Cologuard Plus - TD Cowen
-
Exact Sciences (EXAS) PT Lowered to $70 at BTIG
-
TD Cowen Reiterates Buy Rating on Exact Sciences (EXAS)
-
Pre-Open Movers 1/12: (ARDM) (WATT) (EXAS) (FCEL) (FB) (TMHC) (More..)

